During the recent session, TG Therapeutics Inc (NASDAQ:TGTX)’s traded shares were 0.45 million, with the beta value of the company hitting 2.23. At the last check today, the stock’s price was $34.15, reflecting an intraday loss of -1.16% or -$0.4. The 52-week high for the TGTX share is $36.50, that puts it down -6.88 from that peak though still a striking 64.1% gain since the share price plummeted to a 52-week low of $12.26. The company’s market capitalization is $5.32B, and the average intraday trading volume over the past 10 days was 5.0 million shares, and the average trade volume was 3.74 million shares over the past three months.
TG Therapeutics Inc (TGTX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. TGTX has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.1.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
TG Therapeutics Inc (NASDAQ:TGTX) trade information
TG Therapeutics Inc (TGTX) registered a -1.16% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.16% in intraday trading to $34.15, hitting a weekly high. The stock’s 5-day price performance is 15.60%, and it has moved by 47.06% in 30 days. Based on these gigs, the overall price performance for the year is 169.52%. The short interest in TG Therapeutics Inc (NASDAQ:TGTX) is 32.0 million shares and it means that shorts have 13.37 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies a decrease of -48.48% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $16 and $55 respectively. As a result, TGTX is trading at a discount of -61.05% off the target high and 53.15% off the low.
TG Therapeutics Inc (TGTX) estimates and forecasts
Statistics show that TG Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. TG Therapeutics Inc (TGTX) shares have gone up 104.35% during the last six months, with a year-to-date growth rate more than the industry average at 88.89% against 11.50. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 197.48% this quarter and then jump 292.86% in the quarter after that. In the rating firms’ projections, revenue will increase 40.94% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 98.8M as predicted by 8 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 110.84M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 43.97M and 63.47M respectively. In this case, analysts expect current quarter sales to grow by 124.69% and then jump by 74.62% in the coming quarter.
While earnings are projected to return -40.74% in 2024.
TGTX Dividends
TG Therapeutics Inc is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
TG Therapeutics Inc (NASDAQ:TGTX)’s Major holders
TG Therapeutics Inc insiders own 9.50% of total outstanding shares while institutional holders control 66.32%, with the float percentage being 73.28%. VANGUARD GROUP INC is the largest shareholder of the company, while 393.0 institutions own stock in it. As of 2024-06-30, the company held over 13.69 million shares (or 9.3645% of all shares), a total value of $243.58 million in shares.
The next largest institutional holding, with 11.39 million shares, is of BLACKROCK INC.’s that is approximately 7.7891% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $202.6 million.
Also, the Mutual Funds coming in first place with the largest holdings of TG Therapeutics Inc (TGTX) shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund. Data provided on Sep 30, 2024 indicates that iShares Core S&P Smallcap ETF owns about 8.5 shares. This amounts to just over 5.46 percent of the company’s overall shares, with a $286.96 million market value. The same data shows that the other fund manager holds slightly less at 4.31, or about 2.77% of the stock, which is worth about $145.58 million.
